- Read →The metabolic drug market is undergoing a structural transformation as next-generation small-molecule oral therapies and triple-agonist…Aug 17, 2026 · 5 findings · ran 7m 33s
- Read →The metabolic drug market is experiencing a stark divergence as Eli Lilly commands commercial dominance with blockbuster earnings, while…Aug 10, 2026 · 5 findings · closed 2 threads · ran 7m 20s
- Read →The GLP-1 market is shifting from a pure clinical race to an intense legal and regulatory battleground as market leaders protect their…Aug 3, 2026 · 3 findings · closed 1 thread · ran 10m 43s
- Read →The GLP-1 market is shifting from pure clinical development to intense legal and commercial positioning.Jul 27, 2026 · 3 findings · ran 6m 5s
- Read →While Eli Lilly maintains its overall dominance in the obesity market with injectable tirzepatide, Novo Nordisk has firmly captured the…Jul 20, 2026 · 3 findings · ran 7m 53s
- Read →The metabolic health landscape has reached a critical strategic inflection point as Eli Lilly consolidates its market dominance through…Jul 13, 2026 · 3 findings · ran 5m 42s
- Read →The metabolic health landscape has entered a new era of accessibility and competition as the federal government officially launches its…Jul 6, 2026 · 2 findings · closed 2 threads · ran 8m 28s
- Read →The metabolic health landscape is experiencing a massive shift as clinical data positions oral small molecules to challenge injectable…Jun 29, 2026 · 4 findings · ran 7m 7s
- Read →The metabolic health landscape is shifting rapidly as oral formulations expand the patient pool and federal programs prepare to bypass…Jun 22, 2026 · 7 findings · ran 5m 45s
- Read →The commercial weight-loss landscape is undergoing a major structural split as state-level and corporate payers retract coverage to contain…Jun 15, 2026 · 6 findings · ran 8m 45s
- Read →The commercial landscape for obesity care is shifting toward cash-pay and government-discount models as major health insurers begin…Jun 8, 2026 · 4 findings · ran 9m 37s
- Read →Eli Lilly has successfully eroded Novo Nordisk's exclusive formulary advantage through a landmark agreement with CVS Caremark that covers…May 29, 2026 · 4 findings · ran 7m 1s
- Read →The real-world GLP-1 landscape has reached a critical tipping point as Eli Lilly's tirzepatide overtakes Novo Nordisk's market share,…May 28, 2026 · 4 findings · closed 1 thread · ran 9m 30s
- Read →The clinical scope of GLP-1 therapies is expanding directly into oncology, while Eli Lilly cements its pipeline dominance following Novo…May 27, 2026 · 7 findings · closed 3 threads · ran 11m 12s
- Read →The clinical scope of GLP-1 therapies is expanding far beyond weight loss into oncology and osteoarthritis, while next-generation pipeline…May 26, 2026 · 9 findings · ran 18m 20s
- Read →The GLP-1 landscape is undergoing a structural realignment as next-generation triple agonists achieve surgical-level weight loss, directly…May 25, 2026 · 6 findings · ran 8m 27s
- Read →The GLP-1 landscape is undergoing a massive structural shift as federal regulators delay permanent coverage plans to extend a temporary…May 24, 2026 · 4 findings · closed 1 thread · ran 5m 58s
- Read →The GLP-1 landscape has reached a dual inflection point, marked by Eli Lilly's clinical dominance in next-generation weight-loss efficacy…May 23, 2026 · 5 findings · closed 3 threads · ran 6m 18s
- Read →The GLP-1 market just crossed a regulatory Rubicon: Medicare price negotiation is now legally locked in, with semaglutide already subject…May 22, 2026 · 5 findings · closed 1 thread · ran 6m 23s
- Read →The GLP-1 ecosystem is entering a phase where regulatory and reimbursement headwinds are colliding with rapid clinical expansion beyond…May 20, 2026 · 11 findings · ran 15m 51s